Brief: Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc)
11/03/2025 14:15
March 11 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA THERAPEUTICS ANNOUNCES AGREEMENT WITH MD ANDERSON CANCER CENTER TO EXPLORE APR-1051 AS A POTENTIAL TREATMENT FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) APREA THERAPEUTICS: UNDER TERMS OF AGREEMENT, APREA WILL RETAIN ALL RIGHTS, TITLE, AND INTEREST IN APR-1051 Source text: ID:nGNXb4FmxN Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing